DOI QR코드

DOI QR Code

Bladder Cancer Biomarkers: Review and Update

  • Ghafouri-Fard, Soudeh ;
  • Nekoohesh, Leili ;
  • Motevaseli, Elahe
  • Published : 2014.03.30

Abstract

As the recurrence and mortality rates of bladder cancer are high, research is needed to find suitable biomarkers for early detection, evaluation of prognosis, and surveillance of drug responses. We performed a computerized search of the Medline/PubMed databases with the key words bladder cancer, biomarker, early detection, prognosis and drug response. Several markers were identified at DNA, RNA and protein levels with different sensitivities and specificities. Only a few of the potential bladder cancer biomarkers have been approved for clinical use. Efforts now should be concentrated on finding a panel of markers with acceptable sensitivity and specificity for early detection of bladder cancer.

Keywords

Bladder cancer;biomarker;diagnosis;prognosis

References

  1. Yang N, Feng S, Shedden K, et al (2011). Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res, 17, 3349-59. https://doi.org/10.1158/1078-0432.CCR-10-3121
  2. Wang DL, Lan JH, Chen L, et al (2012). Integrin-linked kinase functions as a tumor promoter in bladder transitional cell carcinoma. Asian Pac J Cancer Prev, 13, 2799-806. https://doi.org/10.7314/APJCP.2012.13.6.2799
  3. Wang, XS, Zhang Z, Wang HC, et al (2006). Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res, 12, 4851-8. https://doi.org/10.1158/1078-0432.CCR-06-0134
  4. Wszolek MF, Rieger-Christ KM, Kenney PA, et al (2011). A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol, 29, 794-801. https://doi.org/10.1016/j.urolonc.2009.08.024
  5. Xiong D, Ye YL, Chen MK, et al (2012). Non-muscle myosin II is an independent predictor of overall survival for cystectomy candidates with early-stage bladder cancer. Oncol Rep, 28, 1625-32.
  6. Yin, B, Liu G, Wang XS, et al (2012). Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder. Urol Oncol, 30, 886-92. https://doi.org/10.1016/j.urolonc.2010.08.017
  7. Yoshino H, Seki N, Itesako T, et al (2013). Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol, 10, 396-404. https://doi.org/10.1038/nrurol.2013.113
  8. Yun SJ, Jeong P, Kim WT, et al (2012). Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol, 41, 1871-8.
  9. Zheng Y, Rodrik V, Toschi A, et al (2006). Phospholipase D couples survival and migration signals in stress response of human cancer cells. J Biol Chem, 281, 15862-8. https://doi.org/10.1074/jbc.M600660200
  10. Tauber S, Brunken C, Vierbuchen M (2011). Expression of the tumormarker p16INK4a in cytology specimens of the urinary bladder. A new means for early recognition and surveillance of urothelial cancer. Urologe A, 50, 1130-3. https://doi.org/10.1007/s00120-011-2693-5
  11. Sun YW, Xuan Q, Shu QA, et al (2013). Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. Genet Mol Res, 12, 1045-53. https://doi.org/10.4238/2013.April.2.21
  12. Svatek RS, Herman MP, Lotan Y, et al (2006). Soluble Fas-a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer, 106, 1701-7. https://doi.org/10.1002/cncr.21795
  13. Tabarestani S, Ghafouri-Fard S (2012). Cancer stem cells and response to therapy. Asian Pac J Cancer Prev, 13, 5951-8.
  14. Tyan YC, Yang MH, Chen SC, et al (2011). Urinary protein profiling by liquid chromatography/tandem mass spectrometry: ADAM28 is overexpressed in bladder transitional cell carcinoma. Rapid Commun Mass Spectrom, 25, 2851-62. https://doi.org/10.1002/rcm.5169
  15. Urquidi V, Goodison S, Kim J, et al (2012a). Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology, 79, 1181-6.
  16. Urquidi V, Goodison S, Ross S, et al (2012b). Diagnostic potential of urinary alpha1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol, 188, 2377-83. https://doi.org/10.1016/j.juro.2012.07.094
  17. Urquidi V, Kim J, Chang M, et al (2012c). CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One, 7, 37797. https://doi.org/10.1371/journal.pone.0037797
  18. Van Le TS, Myers J, Konety BR, Barder T, Getzenberg RH (2004). Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res, 10, 1384-91. https://doi.org/10.1158/1078-0432.CCR-0455-03
  19. Sharma P, Gnjatic S, Jungbluth AA, et al (2003). Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun, 3, 19.
  20. Sartini D, Muzzonigro G, Milanese G, et al (2013). Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urinebased diagnostic test. Cell Biochem Biophys, 65, 473-83. https://doi.org/10.1007/s12013-012-9451-1
  21. Scher MB, Elbaum MB, Mogilevkin Y, et al (2012). Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol, 188, 2101-7. https://doi.org/10.1016/j.juro.2012.08.015
  22. Shariat SF, Savage C, Chromecki TF, et al (2011). Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer, 117, 2892-7. https://doi.org/10.1002/cncr.25903
  23. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  24. Smith ZL, Guzzo TJ (2013). Urinary markers for bladder cancer. F1000Prime Rep, 5, 21.
  25. Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR (2012). A pilot study of urinary microRNAas a biomarker for urothelial cancer. Can Urol Assoc J, 15, 1-5.
  26. Srivastava AK, Singh PK, Srivastava K, et al (2013). Diagnostic role of survivin in urinary bladder cancer. Asian Pac J Cancer Prev, 14, 81-5. https://doi.org/10.7314/APJCP.2013.14.1.81
  27. Stoeber K, Swinn R, Prevost AT, et al (2002). Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst, 94, 1071-9. https://doi.org/10.1093/jnci/94.14.1071
  28. Qin ZK, Yang JA, Ye YL, et al (2009). Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer, 9, 61. https://doi.org/10.1186/1471-2407-9-61
  29. Orenes-Pinero E, Corton M, Gonzalez-Peramato P, et al (2007). Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res, 6, 4440-8. https://doi.org/10.1021/pr070368w
  30. Pesch B, Taeger D, Johnen G, et al (2013). Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int Arch Occup Environ Health, [Epub ahead of print].
  31. Pignot G, Cizeron-Clairac G, Vacher S, et al (2013). microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer, 132, 2479-91. https://doi.org/10.1002/ijc.27949
  32. Qin ZK, Yang JA, Zeng MS, et al (2008). Expression and clinical significance of Bmi-1 protein in bladder cancer. Ai Zheng, 27, 1327-30.
  33. Rahmani AH, Alzohairy M, Babiker AY, et al (2013). Implication of androgen receptor in urinary bladder cancer: a critical mini review. Int J Mol Epidemiol Genet, 4, 150-5.
  34. Rasmussen HH, Orntoft TF, Wolf H, Celis JE (1996). Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol, 155, 2113-9. https://doi.org/10.1016/S0022-5347(01)66119-6
  35. Rosser CJ, Ross S, Chang M, et al (2013). Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol, 190, 2257-62. https://doi.org/10.1016/j.juro.2013.06.011
  36. Sakaki M, Oka N, Nakanishi R, et al (2008). Serum level of galectin-3 in human bladder cancer. J Med Invest, 55, 127-32. https://doi.org/10.2152/jmi.55.127
  37. Sanchini MA, Gunelli R, Nanni O, et al (2005). Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA, 294, 2052-6. https://doi.org/10.1001/jama.294.16.2052
  38. Miah S, Dudziec E, Drayton RM, et al (2012). An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer, 107, 123-8. https://doi.org/10.1038/bjc.2012.221
  39. Lorenzi T, Lorenzi M, Altobelli E, et al (2013). HtrA1 in human urothelial bladder cancer: a secreted protein and a potential novel biomarker. Int J Cancer, 133, 2650-61.
  40. Matsuda R, Enokida H, Chiyomaru T, et al (2011). LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling. Br J Cancer, 104, 376-86. https://doi.org/10.1038/sj.bjc.6605990
  41. Mengus C, Schultz-Thater E, Coulot J, et al (2013). MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas. Int J Cancer, 132, 2459-63. https://doi.org/10.1002/ijc.27914
  42. Myers-Irvin JM, Van Le TS, Getzenberg RH (2005). Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Cancer Res, 65, 7145-50. https://doi.org/10.1158/0008-5472.CAN-05-1142
  43. Nana-Sinkam SP, Croce CM (2013). Clinical applications for microRNAs in cancer. Clin Pharmacol Ther, 93, 98-104. https://doi.org/10.1038/clpt.2012.192
  44. Nielsen ME, Gonzalgo ML, Schoenberg MP, Getzenberg RH (2006). Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. World J Urol, 24, 499-508. https://doi.org/10.1007/s00345-006-0116-9
  45. Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, et al (2012). miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics, 5, 40. https://doi.org/10.1186/1755-8794-5-40
  46. Obara W, Ohsawa R, Kanehira M, et al (2012). Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol, 42, 591-600. https://doi.org/10.1093/jjco/hys069
  47. Omran OM (2012). CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma. J Environ Pathol Toxicol Oncol, 31, 203-12. https://doi.org/10.1615/JEnvironPatholToxicolOncol.v31.i3.20
  48. Kompier LC, Lurkin I, van der Aa MN, et al (2010). FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One, 5, 13821. https://doi.org/10.1371/journal.pone.0013821
  49. Karbakhsh M, Dabbagh N, Shabani A, TabibiA,Akhavizadegan H (2013). Age at diagnosis in bladder cancer: does opium addiction play a role? Asian Pac J Cancer Prev, 14, 4723-5. https://doi.org/10.7314/APJCP.2013.14.8.4723
  50. Kelly JD, Dudderidge TJ, Wollenschlaeger A (2012). Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22. PLoS One, 7, 40305. https://doi.org/10.1371/journal.pone.0040305
  51. Kohler CU, Bryk O, Meier S, et al (2013). Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers. Biochem Biophys Res Commun, 438, 48-53. https://doi.org/10.1016/j.bbrc.2013.07.021
  52. Lai Y, Ye J, Chen J, et al (2010). UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology, 76, 25. https://doi.org/10.1016/j.urology.2010.03.011
  53. Laurberg JR, Brems-Eskildsen AS, Nordentoft I, et al (2012). Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatmentspecific outcome of localised invasive bladder cancer. BJU Int, 110, 9.
  54. Lei Y, Yan S, Ming-De L, Na L, Rui-Fa H (2011). Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem, 113, 514-8. https://doi.org/10.1016/j.acthis.2010.05.004
  55. Linden M, Segersten U, Runeson M, et al (2013). Tumour expression of bladder cancer-associated urinary proteins. BJU Int, 112, 407-15. https://doi.org/10.1111/j.1464-410X.2012.11653.x
  56. Lindgren D, Liedberg F, Andersson A, et al (2006). Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene, 25, 2685-96. https://doi.org/10.1038/sj.onc.1209249
  57. Hoque MO, Begum S, Topaloglu O, et al (2006). Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst, 98, 996-1004. https://doi.org/10.1093/jnci/djj265
  58. Hanke M, Hoefig K, Merz H, et al (2010). Arobust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol, 28, 655-61. https://doi.org/10.1016/j.urolonc.2009.01.027
  59. Ho CC, Tan WP, Pathmanathan R, Tan WK, Tan HM (2013). Fluorescence-in-situ-hybridization in the surveillance of urothelial cancers: can use of cystoscopy or ureteroscopy be deferred? Asian Pac J Cancer Prev, 14, 4057-9. https://doi.org/10.7314/APJCP.2013.14.7.4057
  60. Holterman DA, Diaz JI, Blackmore PF, et al (2006). Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol Oncol, 24, 97-108. https://doi.org/10.1016/j.urolonc.2005.07.010
  61. Hu HY, Hu ZL, Wang HQ, Liu C, Yu SJ (2012). Nuclear matrix protein 22 and urinary cytology test in the diagnosis of bladder cancer: a meta-analysis. Zhonghua Wai Ke Za Zhi, 50, 1126-30.
  62. Irani J, Desgrandchamps F, Millet C, Toubert ME, et al (1999). BTAstat and BTATRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur Urol, 35, 89-92. https://doi.org/10.1159/000019824
  63. Irmak S, Tilki D, Heukeshoven J, et al (2005). Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics, 5, 4296-304. https://doi.org/10.1002/pmic.200402005
  64. Johnen G, Gawrych K, Bontrup H, et al (2012). Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen. PLoS One, 7, 16.
  65. Karam JA, Lotan Y, Karakiewicz PI, (2007). Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol, 8, 128-36. https://doi.org/10.1016/S1470-2045(07)70002-5
  66. Ghafouri-Fard S, Modarressi MH (2012). Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. Immunotherapy, 4, 59-75. https://doi.org/10.2217/imt.11.145
  67. Ghafouri-Fard S, Ghafouri-Fard S (2012). Immunotherapy in nonmelanoma skin cancer. Immunotherapy, 4, 499-510. https://doi.org/10.2217/imt.12.29
  68. Ghafouri-Fard S, Abdollahi DZ, Omrani M, Azizi F (2012). shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines. Asian Pac J Cancer Prev, 13, 5865-9. https://doi.org/10.7314/APJCP.2012.13.11.5865
  69. Ghafouri-Fard S, Modarressi MH (2009). Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 12, 395-404.
  70. Ghafouri-Fard S, Ousati Ashtiani Z, Sabah Golian B, Hasheminasab SM, Modarressi MH (2010). Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Arch Med Res, 41, 195-200. https://doi.org/10.1016/j.arcmed.2010.04.003
  71. Gibanel R, Ribal MJ, Filella X, et al (2002). BTA TRAK urine test increases the efficacy of cytology in the diagnosis of lowgrade transitional cell carcinoma of the bladder. Anticancer Res, 22, 1157-60.
  72. Goodison S, Rosser CJ, Urquidi V (2013). Bladder cancer detection and monitoring: assessment of urine- and bloodbased marker tests. Mol Diagn Ther, 17, 71-84. https://doi.org/10.1007/s40291-013-0023-x
  73. Griffiths TR (2013). Current perspectives in bladder cancer management. Int J Clin Pract, 67, 435-48. https://doi.org/10.1111/ijcp.12075
  74. Guo B, Luo C, Xun C, et al (2009). Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR. Exp Oncol, 31, 43-7.
  75. Guo Y, Ying L, Tian Y, et al (2013). miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J, 280, 4531-8. https://doi.org/10.1111/febs.12417
  76. Chen YT, Chen CL, Chen HW, et al (2010). Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res, 9, 5803-15. https://doi.org/10.1021/pr100576x
  77. Bhagirath D, Abrol N, Khan R, et al (2012). Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder. Clin Chim Acta, 413, 1641-6. https://doi.org/10.1016/j.cca.2012.05.005
  78. Brems-Eskildsen AS, Zieger K, Toldbod H, et al (2010). Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer, 10, 646. https://doi.org/10.1186/1471-2407-10-646
  79. Chen CL, Lai YF, Tang P, et al (2012). Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res, 11, 5611-29.
  80. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS (2013). Recent advances in the diagnosis and treatment of bladder cancer. BMC Med, 11, 13. https://doi.org/10.1186/1741-7015-11-13
  81. Chihara Y, Kanai Y, Fujimoto H, et al (2013). Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer, 13, 275. https://doi.org/10.1186/1471-2407-13-275
  82. Dhawan D, Hamdy FC, Rehman I, et al (2006). Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol, 209, 336-43. https://doi.org/10.1002/path.1991
  83. Eissa S, Kassim SK, Labib RA, et al (2005). Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer, 103, 1356-62. https://doi.org/10.1002/cncr.20902
  84. Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR (2009). Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res, 15, 1024-31. https://doi.org/10.1158/1078-0432.CCR-08-1143
  85. Frantzi M, Makridakis M, Vlahou A (2012). Biomarkers for bladder cancer aggressiveness. Curr Opin Urol, 22, 390-6. https://doi.org/10.1097/MOU.0b013e328356ad0e
  86. Abogunrin F, O'Kane HF, Ruddock MW, et al (2012). The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer, 118, 2641-50. https://doi.org/10.1002/cncr.26544
  87. Alvarez A, Lokeshwar VB (2007). Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol, 17, 341-6. https://doi.org/10.1097/MOU.0b013e3282c8c72b
  88. Babjuk M, Kostirova M, Mudra K, et al (2002). Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol, 41, 34-9. https://doi.org/10.1016/S0302-2838(01)00015-X
  89. Bangma CH, Loeb S, Busstra M, et al (2013). Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol, 64, 41-7. https://doi.org/10.1016/j.eururo.2013.02.036
  90. Bergeron A, Picard V, LaRue H, et al (2009). High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer, 125, 1365-71. https://doi.org/10.1002/ijc.24503

Cited by

  1. Accuracy of Preoperative Urinary Symptoms, Urinalysis, Computed Tomography and Cystoscopic Findings for the Diagnosis of Urinary Bladder Invasion in Patients with Colorectal Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7241
  2. microRNA-195 inhibits cell proliferation in bladder cancer via inhibition of cell division control protein 42 homolog/signal transducer and activator of transcription-3 signaling vol.10, pp.3, 2015, https://doi.org/10.3892/etm.2015.2633
  3. Can Recurrence and Progression be Predicted by HYAL-1 Expression in Primary T1 Bladder Cancer? vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10401
  4. Prognostic Significance of Nestin Expression in pT1 High-Grade Bladder Urothelial Carcinoma Patients Treated with Intravesical BCG vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10813
  5. Significance of Suppressor of Cytokine Signaling-3 Expression in Bladder Urothelial Carcinoma in Relation to Proinflammatory Cytokines and Tumor Histopathological Grading vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.307
  6. High Expression Level of Preoperative Serum Uroplakin III is Associated with Biologically Aggressive Bladder Cancer vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1539
  7. Intrinsic Tumour Factors Affecting Recurrence in Non Muscle Invasive Bladder Cancer: a Hospital Based Study from India vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2675
  8. Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells vol.5, pp.1, 2015, https://doi.org/10.1038/srep12870
  9. Molecular markers in bladder cancer: Novel research frontiers vol.52, pp.5, 2015, https://doi.org/10.3109/10408363.2015.1033610
  10. Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3337
  11. MicroRNA-101 inhibits the proliferation and invasion of bladder cancer cells via targeting c-FOS vol.14, pp.3, 2016, https://doi.org/10.3892/mmr.2016.5534
  12. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy vol.9, pp.12, 2017, https://doi.org/10.2217/imt-2017-0083
  13. Melanoma: a prototype of cancer-testis antigen-expressing malignancies vol.9, pp.13, 2017, https://doi.org/10.2217/imt-2017-0091
  14. Long non-coding RNA expression in bladder cancer pp.1867-2469, 2017, https://doi.org/10.1007/s12551-017-0379-y
  15. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy vol.7, pp.4, 2015, https://doi.org/10.2217/imt.15.3
  16. Expression analysis of a panel of cancer-testis antigens in bladder cancer pp.1744-828X, 2018, https://doi.org/10.2217/pme-2018-0049